small molecule

KAZANO

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

Loss of exclusivityMay 2029latest FDA-listed patent expiry

CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand name	KAZANO
Active ingredient	ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE
Strength	EQ 12.5MG BASE;1GM
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	January 2013
Marketing status	RX

Listed patents

Patent	Expires	Type
8900638	May 2029	product
7807689	June 2028	substance, product

Regulatory exclusivity

Code	Expires
M-300	July 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from TAKEDA PHARMACEUTICALS USA INC